GT-101

Tumor-Infiltrating Lymphocytes (TIL) therapy represents a groundbreaking approach in cancer treatment, offering new hope for patients with difficult-to-treat cancers. This article delves into the clinical trial landscape of TIL therapy, highlighting its potential to revolutionize oncology through targeted immunotherapy. With a focus on the latest research and findings, including the FDA's approval of AMTAGVI for advanced melanoma, the piece explores the challenges and future directions of TIL therapy in enhancing cancer treatment efficacy and safety.

Grit Biotechnology's GT201, a genetically engineered tumor-infiltrating lymphocyte (TIL) therapy, has been cleared by the FDA for clinical trials in advanced solid tumors.